Business Wire

Successful Certification of Kalray’s Smart Storage Adapter

Share

Kalray (Paris:ALKAL) (Euronext Growth Paris: FR0010722819 – ALKAL), a pioneer in processors for new intelligent systems, today announced that its K200™ Coolidge™ based smart storage adapter solution has been certified for NVM ExpressTM over Fabrics (NVMe-oF) with TCP (NVMe™/TCP) protocol by the NVM Express organization through the University of New Hampshire InterOperability Laboratory (UNH-IOL), an independent testing provider of standard conformance solutions and multi-vendor interoperability.

Data Centers are undergoing a very important revolution with rapidly evolving network architectures and technologies. This is mainly due to the explosion of usages, the surge of data to be processed and the resulting exponential growth of the number of machines to be managed to support this growth.

Until now, storage has been one major bottleneck of this expansion. The introduction of flash memory-based SDD (Solid-State Drive) with hyper-fast communication protocols such as NVMe™/TCP, offers a breakthrough solutions to the industry to massively scale up and increase performance of existing data centers. Smart storage adapters and associated storage appliances (including Ethernet storage expansion servers called “JBOF”) are at the heart of this revolution.

Dennis Hahn, Senior Analyst, Cloud & Data Center at OMDIA stated in his report, Data Center Storage Equipment Market Tracker: “NVMe-oF JBOF is just starting to experience an uptake in on-premises enterprise DC segments for its ultra-high performance and is ramping aggressively for use by hyper converged infrastructure and in data intensive applications”.

Eric Baissus, President and CEO of Kalray, has declared: “Certification is a major step in our journey to mass production. Kalray is on schedule with its strategic roadmap and actively preparing the commercial deployment of a new type of hyper-fast storage solution. Together with our partners and customers, we are actively working to integrate and qualify our technology and products”.

Based on its 3rd generation MPPA® (Massively Parallel Processor Array) processor, Kalray’s storage smart adapter solution, targets the new generations of hyper-fast storage solutions. Whereas competitive solutions are limited in term of performance, for example when demanding algorithms such as data protection and footprint reduction are running, Coolidge™ Intelligent processors have the capability to run such protocols without degradation of the server bandwidth, in real time. Kalray’s fully programmable smart storage adapter delivers high performance while ensuring offloading of demanding data services. This Coolidge™-based solution also offers new horizons in term of storage performance, targeting the booming market of data intensive application such as AI, Data Analytics or IoT.

Kalray's solution offers both extremely high computing power capable of processing considerable data volumes while minimizing energy consumption; as well as on-the-fly heterogenous processing capabilities. The K200™ smart storage adapter is a standard PCIe card supporting both NVMe™/TCP and NVMe™/RoCE, with associated software suite, highly configurable for composability needs, based on its MPPA® processor implementing leading edge interfaces, including PCIe Gen4 x16 and 2 x 100G Ethernet. As an example, coupled with the latest PCIe Gen4 AMD processor MPPA® can be used as an accelerator delivering a full duplex bandwidth of up to 200 Gbit/s. In addition, K200™ delivers up to 4 MIOPS (Millions of I/O Operations Per Second).

For more information, please contact Kalray’s sales team at contact@kalrayinc.com

ABOUT KALRAY

Kalray (Euronext Growth Paris - FR0010722819 - ALKAL) is a fabless semiconductor company, pioneer in a new generation of processors for intelligent systems. MPPA® Intelligent processors are able to capture and analyze on the fly massive data flows, close to where they are generated, and interact in real time with the outside world. These processors are capable of running demanding AI algorithms and simultaneously a wide set of different processing and control tasks such as mathematical algorithms, signal processing, network or storage software stacks. Kalray’s Intelligent Processors can be deployed in fast-growing sectors of Edge Computing and AI: Modern data centers, networks (5G), autonomous vehicles, healthcare equipment, industry 4.0, drones and robots… Kalray’s offering includes processors, system boards and a software suite, for a broad spectrum of customers such as data storage systems and compute server manufacturers, intelligent system integrators and consumer product manufacturers such as car makers. Founded in 2008 as a spin-off of CEA French lab, Kalray counts among its investors: Alliance Venture (Renault-Nissan-Mitsubishi), Safran, NXP Semiconductors, CEA and Bpifrance. Read more at: www.kalrayinc.com

Contact information

INVESTOR CONTACTS
Eric BAISSUS
contactinvestisseurs@kalray.eu
Tel. +33 (0)4 76 18 90 71

ACTUS finance & communication
Jérôme FABREGUETTES-LEIB
kalray@actus.fr
+ 33 1 53 67 36 78

MEDIA CONTACTS
Loic HAMON
communication@kalray.eu
Tel. +33 (0)4 76 18 90 71

ACTUS finance & communication
Serena BONI
sboni@actus.fr
Tel. +33 (0)4 72 18 04 92

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia Pacific1.12.2020 00:00:00 CETPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to Celltrion Inc. (“Celltrion”) for a total value of $278 million USD inclusive of milestone payments. The portfolio includes 18 pharmaceutical products and over-the-counter (OTC) products sold in Asia Pacific, which is part of Takeda’s Growth & Emerging Markets Business Unit. This divestment agreement was first announced in June 2020. The divested portfolio includes pharmaceutical products and OTC products in the Cardiovascular, Diabetes and General Medicine therapeutic areas, sold in Australia, Hong Kong, Macau, Malaysia, Philippines, Singapore, South Korea, Taiwan and Thailand. The products, while addressing key patient needs in these countries and territories, are outside of the business areas Takeda has chosen as core to its global long-term growth. As part of the deal, Takeda will continue to manufacture the portfol

Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited1.12.2020 00:00:00 CETPress release

Celltrion (KRX:068270) has completed the acquisition of select primary care assets from Takeda Pharmaceutical Company Limited (“Takeda”) in Asia Pacific, igniting efforts to strengthen its R&D capability in the global small molecule pharmaceuticals business. In June, the firms announced an agreement under which Celltrion would acquire 18 "Primary Care" product assets in the Asia Pacific area for a total of USD 278 million inclusive of milestone payments from Takeda. Celltrion proceeded with the acquisition process through its newly established subsidiary in Singapore, "Celltrion Asia Pacific Pte, Ltd."1 ("Celltrion APAC"). Upon completion of the acquisition, Celltrion APAC will assume the ownership of the rights to patents, trademarks, and sales of 18 products sold in 9 markets including South Korea, Thailand, Taiwan, Hong Kong, Macau, the Philippines, Singapore, Malaysia, and Australia. The 18 products include prescription medicines such as Nesina (diabetes), Actos (diabetes), and Eda

Ipsen Receives FDA Fast Track Designation for Investigational Irinotecan Liposome Injection (ONIVYDE ® ) as a Second-Line Monotherapy Treatment for Small Cell Lung Cancer (SCLC)30.11.2020 22:58:00 CETPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the United States Food and Drug Administration (FDA) has granted the company Fast Track designation for irinotecan liposome injection (ONIVYDE®) in study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen, reflecting the unmet medical need. ONIVYDE® is currently approved in the United States and in Europe in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. ONIVYDE® is not indicated as a single agent for the treatment of patients with metastatic adenocarcinoma of the pancreas. An ongoing Phase III randomized study (RESILIENT; NCT03088813) trial is being conducted to assess the efficacy and safety of investigational irinotecan liposome injection (ONIVYDE®) as a monotherapy for SCLC study patients who have progressed on or a

Amblin Partners Announces New Multi-Year Film Distribution Partnership With Universal Filmed Entertainment Group30.11.2020 22:00:00 CETPress release

Amblin Partners today announced a new multi-year film distribution partnership with Universal Filmed Entertainment Group, as well as a series of new agreements that chart a clear course for the next phase of growth for one of the world’s leading independent film and television studios. The new deals were announced this morning by Steven Spielberg, Amblin’s Founder and Chairman. Remarked Spielberg: “My decades-long relationship with Universal truly transcends any single business deal, and to once again renew our corporate vows reaffirms that Universal is Amblin’s home. In addition to Universal, we are blessed to continue forward with a global family of partners, including Alibaba, eOne and Reliance, each of which has supported us for many years and enabled our storytelling to touch the lives of millions of moviegoers around the world. I would also like to extend my deepest gratitude to my dear friends Jeff Skoll and David Linde for an incredible run as formal partners; and my congratula

Little Cinema Taps Verimatrix To Secure Hollywood’s Virtual Premiere Events30.11.2020 17:45:00 CETPress release

Regulatory News: Verimatrix, (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that New York-based Little Cinema deployed Verimatrix Watermarking and Multi-DRM technologies for its virtual premieres and previews. A groundbreaking digital studio, Little Cinema has partnered with Netflix, ABC, CBS, HBO Max, and Warner Media to produce state-of-the-art virtual premiere events for an industry that used to rely solely on in-person debuts. To fulfill the enhanced protection requirements for this high-value early-release content, Little Cinema looked to Verimatrix and its Secure Cloud. These innovative and highly-interactive virtual streaming events have made waves in Hollywood, earning the studio recognition in BBC News, Vogue, Variety, Vanity Fair, The Hollywood Reporter, and more. “Verimatrix supplies us with the needed anti-piracy protections and overall peace of mind that Hollywood studios demand when switching to virtual events

Emory University to Host a Live Webcast With His Holiness the Dalai Lama30.11.2020 16:39:00 CETPress release

The Center for Contemplative Science and Compassion-Based Ethics at Emory University will host a live webinar with His Holiness the Dalai Lama on Tuesday, December 8, 2020. A discussion titled “The Necessity of Compassion for the Survival of Humanity” will feature the Dalai Lama in conversation with Melani A. Walton, co-founder of the Rob and Melani Walton Foundation, and Dr. Sanjay Gupta, chief medical correspondent for CNN. (For speaker photos click here.) The webcast begins at 10:30pm ET on Dec. 8, 2020 (Dec. 9 @ 9:00am India Standard Time) and will be simulcast in 14 languages. It is FREE of charge and open to anyone who’d like to participate. Advance registration is encouraged at https://compassionshift.emory.edu. “With so many urgent concerns impacting our world, the time is right to start a global conversation about the importance of compassion,” said Lobsang Tenzin Negi, executive director of Emory University’s Center for Contemplative Science and Compassion-Based Ethics. “For